Breast Cancer Liquid Biopsy Market Will Grow USD 642.9 Million By 2024, Globally: Zion Market Research

According to the report, global breast cancer liquid biopsy market was valued at approximately USD 151.8 million in 2017 and is expected to generate revenue of around USD 642.9 million by end of 2024, growing at a CAGR of around 22.9% between 2018 and 2024.


New York, NY, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Breast Cancer Liquid Biopsy Market by Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers) and End User (Reference Laboratories, Hospitals and Physician Laboratories, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”. According to the report, global breast cancer liquid biopsy market was valued at approximately USD 151.8 million in 2017 and is expected to generate revenue of around USD 642.9 million by end of 2024, growing at a CAGR of around 22.9% between 2018 and 2024.

Liquid biopsy assesses the presence of tumor cell-derived biomarkers such as cell-free DNA (cfDNA), circulating tumor cells, extracellular vesicles (exosomes) and their cargo, proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is simpler, noninvasive, and cost-effective diagnostic tool for cancer. Liquid biopsy uses body fluids as a sample for analysis mainly blood. The amount of circulating biomarkers varies among healthy individuals and cancer patients and thus acts as a valuable tool for both early diagnosis of cancer as well as monitoring the disease progression in advanced stages of cancer to assess heterogeneity of tumor cells. Breast cancer is the second most common malignancy worldwide and thus liquid biopsy is an extremely important tool for breast cancer diagnosis and evaluation.

Browse through 61 Tables & 22 Figures spread over 110 Pages and in-depth TOC on “Global Breast Cancer Liquid Biopsy Market: By Type, Size, Share, Industry Growth Analysis and Forecast, 2017 - 2024”.

Request Free Sample Report of Global Breast Cancer Liquid Biopsy Market Report @ https://www.zionmarketresearch.com/sample/breast-cancer-liquid-biopsy-market

Factors such as increasing prevalence of breast cancer among women worldwide, inclination towards noninvasive procedures, government fundings, and initiatives, increasing awareness about cancer along with rising healthcare expenditure are driving the growth of the breast cancer liquid biopsy market. Additionally, technological advancements along with continuous research and development in the field of cancer and preference for personalized medicines are impacting the growth of the market. Nevertheless, the high cost of the tests, lack of trained professional, and fewer reimbursement policies can restrict the growth of the global breast cancer liquid biopsy market.

The global breast cancer liquid biopsy market has been segmented into biomarkers, end-user, and region. The biomarker segment has been classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs) and others. Others segment includes circulating biomarkers such as cell-free protein biomarkers and circulating RNA (ctRNA and cfRNA). Cell-free DNA segment holds the maximum share of the biomarker segment. End users of breast cancer liquid biopsy market are physician laboratories and hospitals, reference laboratories, and other. Other end users include research institutes, pathology laboratories, academic research centers, etc.

Download Free Report Brochure: https://www.zionmarketresearch.com/requestbrochure/breast-cancer-liquid-biopsy-market

North America represents a developed regional market for breast cancer liquid biopsy and is expected to see the rapid growth in the years to come. The U.S. is by far the leading breast cancer liquid biopsy market by country in North America. The U.S. market is projected to show rapid growth during the forecast period. Well developed healthcare infrastructure, huge investments in research and development and presence of key market players are factors contributing to the growth of the market in this region. Moreover, the government fund/grant will promote the growth of breast cancer liquid biopsy market.

Second largest region for the breast cancer liquid biopsy market was Europe and is projected to show considerable growth in the forecast period. Increase in prevalence of cancer worldwide and favorable reimbursement policies will drive the market growth.

Browse the full "Breast Cancer Liquid Biopsy Market by Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers) and End User (Reference Laboratories, Hospitals and Physician Laboratories, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/breast-cancer-liquid-biopsy-market

Asia Pacific will grow at the highest rate over the forecast period. In Asia, India, China, and Japan are expected to be fastest growing in breast cancer liquid biopsy market. Growth in this market is driven by dense population base and increased prevalence of cancer. Other factors influencing the market growth are increasing health awareness among people along with increasing disposable income.

In Middle East & Africa; lack of awareness will lead to medium growth in African countries. Medium growth is expected in the Latin America region over the forecast period.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/breast-cancer-liquid-biopsy-market

Some of the key players in the breast cancer liquid biopsy market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc., Biodesix, Inc., Guardant Health, Inc., and Isogen Life Science B.V., among others.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/3302

This report segments the global breast cancer liquid biopsy market as follows:

Global Breast Cancer Liquid Biopsy Market: By Biomarker

  • Circulating Tumor Cells (CTCs)
  • Cell-free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers (ctRNA, cfRNA, and cell-free proteins)

Global Breast Cancer Liquid Biopsy Market: By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Other End Users

Global Breast Cancer Liquid Biopsy Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research

Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

Contact Us:

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com